{
    "2021-06-04": [
        [
            {
                "time": "2021-06-04",
                "original_text": "FDA approves Novo Nordisk’s obesity drug Wegovy, which helped people cut weight 15%",
                "features": {
                    "keywords": [
                        "FDA",
                        "Novo Nordisk",
                        "Wegovy",
                        "obesity drug",
                        "weight cut"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-06-04",
                "original_text": "UPDATE 2-U.S. FDA approves Novo Nordisk's semaglutide as obesity treatment",
                "features": {
                    "keywords": [
                        "FDA",
                        "Novo Nordisk",
                        "semaglutide",
                        "obesity treatment"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-06-04",
                "original_text": "Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US",
                "features": {
                    "keywords": [
                        "Wegovy",
                        "semaglutide",
                        "GLP-1 therapy",
                        "weight management",
                        "US approval"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}